New drug DS1025a takes on advanced solid tumors in first human trial

NCT ID NCT07681882

Recruiting now Disease control Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Aug 11, 2026 · Updated 5 times

Summary

This trial is testing a new drug called DS1025a in people with advanced solid tumors that have spread, cannot be removed by surgery, or have stopped responding to other treatments. The main goals are to check the drug's safety, how the body processes it, and whether it shows any signs of shrinking tumors. This is the first time DS1025a is being tested in humans, so it is a small, early-stage study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DS1025a
What this could lead to: If safe and effective, DS1025a could offer a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is an early, small phase 1 trial focused on safety, so it is unknown if DS1025a will effectively shrink tumors or improve survival. Side effects are possible and will be closely monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR METASTATIC SOLID TUMOR UNRESECTABLE SOLID TUMOR

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Kansai Medical University Hospital
RECRUITING

Osaka, 573-1191, Japan
The Cancer Institute Hospital of JFCR
NOT_YET_RECRUITING

Tokyo, 135-8550, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.